ANTI-VINCULIN CLONE 7F9 ZOOMAB MOUSE MONOCLONAL (C15-1671-435)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 7F9 is a ZooMAb^® Mouse recombinant monoclonal antibody that specifically detects Vinculin.

Immunogen

Crude smooth muscle extract from normal human adult uterus.

Application

Quality Control Testing

Evaluated by Western Blotting in PC12 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Vinculin in PC12 cell lysate.

Tested applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Vinculin in HepG2 cell lysate.

Immunoprecipitation Analysis: A representative lot of mouse monoclonal antibody (Clone 7F9) immunoprecipitated Vinculin in Immunoprecipitation applications. (Bays, JL., et al. (2014). J. Cell Biol. 205(2); 251-263).

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Vinculin in HepG2 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected Vinculin in human kidney and human colon tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Target description

Vinculin (UniProt: P18206; also known as Metavinculin, MV) is encoded by the VCL gene (Gene ID: 7414) in human. Vinculin is a muscle-specific, peripheral membrane protein that serves as an actin filament binding protein involved in cell-matrix adhesion and cell-cell adhesion. It regulates cell-surface E-cadherin expression and potentiates mechano-sensing by the E-cadherin complex. Its recruitment to cell-cell junctions is reported to occur in a myosin II-dependent manner and its interaction with catenin- b1 is shown to be essential for its localization to the cell-cell junctions. Vinculin exists in at least two conformations. When in the closed, inactive conformation, extensive interactions between its head and tail domains prevent detectable binding to most of its ligands. It takes on an active conformation after cooperative and simultaneous binding of two different ligands. This activation involves displacement of the head-tail interactions. The active form binds a number of proteins that have both signaling and structural roles that are important for cell adhesion. The N-terminal globular head (aa 1-835; Vh) contains subdomains D1-D4. The C-terminal tail (aa 879-1134; Vt) region binds F-actin and cross-links actin filaments into bundles. An intramolecular interaction between Vh and Vt regions masks the F-actin-binding domain that is located in Vt region. Mutations in VCL gene are reported to cause familial hypertrophic cardiomyopathy that is characterized by asymmetric ventricular hypertrophy leading to dyspnea, syncope, collapse, palpitations, and chest pain. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Clainche, CL., et al. (2010). J. Biol. Chem. 285(30); 23420-23432; Vasile, VC., et al. (2006). Biochem. Biophys. Res. Commun. 345(3); 998-1003).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.